On the stock market since 1995, it operates in the world of health and science. It has 282 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (4% a year).
If every debt were paid off today, $33.2M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 15% below its peak. The market has trimmed its expectations for the company.
There is $35.1M in the vault; even if every debt were paid off, $33.2M would remain.
Over the last 12 months, company executives reported 4 buys and 1 sell. Management buying with its own money is usually read as a good sign.
The stock sits at $0.30. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, VASO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VASO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.